Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.44 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.39 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL28426122 | 1.00 | LPAR3 (0.44) | LPAR3LPAR1LPAR2CYP3A4MEN1 | |
| SCHEMBL497177 | 0.97 | LPAR3 (0.46) | LPAR3LPAR1LPAR2CYP3A4MEN1 | |
| SCHEMBL28780969 | 0.94 | LPAR3 (0.44) | LPAR3LPAR1LPAR2CYP3A4MEN1 | |
| SCHEMBL19712779 | 0.94 | LPAR3 (0.44) | LPAR3LPAR1LPAR2CYP3A4MEN1 | |
| SCHEMBL28780965 | 0.94 | LPAR3 (0.44) | LPAR3LPAR1LPAR2CYP3A4MEN1 | |
| SCHEMBL7263489 | 0.94 | LPAR3 (0.44) | LPAR3LPAR1LPAR2CYP3A4MEN1 | |
| SCHEMBL11754891 | 0.94 | LPAR3 (0.44) | LPAR3LPAR1LPAR2CYP3A4MEN1 | |
| Hydrochloric Acid SCHEMBL11037593 | 0.94 | LPAR3 (0.44) | LPAR3LPAR1LPAR2CYP3A4MEN1 | |
| SCHEMBL7005822 | 0.94 | LPAR3 (0.44) | LPAR3LPAR1LPAR2CYP3A4MEN1 | |
| Bromide SCHEMBL11421248 | 0.94 | LPAR3 (0.44) | LPAR3LPAR1LPAR2CYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1365 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055056-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | WILLIAM M YARBROUGH FOUND (US) | 2026-02-26 | — | — | US | claimed |
| US-12310939-B2 | Method for treating rheumatoid arthritis | THE WILLIAM YARBROUGH FOUNDATION (US) | 2025-05-27 | — | — | US | claimed |
| US-20250161258-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | THE WILLIAM M YARBROUGH FOUND (US) | 2025-05-22 | — | — | US | claimed |
| CN-119776078-A | Cleaning composition | 宝洁公司 | 2025-04-08 | — | — | CN | claimed |
| US-12239626-B2 | Method for treating infectious diseases with isothiocyanate functional compounds | THE WILLIAM YARBROUGH FOUNDATION (US) | 2025-03-04 | — | — | US | claimed |
| US-20250011688-A1 | COMPOSITION | PROCTER & GAMBLE (US) | 2025-01-09 | — | — | US | claimed |
| US-12178795-B2 | Method for treating metastatic prostate cancer | THE WILLIAM YARBROUGH FOUNDATION (US) | 2024-12-31 | — | — | US | claimed |
| US-20230338324-A1 | METHOD FOR TREATING RHEUMATOID ARTHRITIS | THE WILLIAM M YARBROUGH FOUNDATION | 2023-10-26 | — | — | US | claimed |
| US-20230263763-A1 | METHOD FOR TREATING INFECTIOUS DISEASES WITH ISOTHIOCYANATE FUNCTIONAL COMPOUNDS | THE WILLIAM M YARBROUGH FOUNDATION | 2023-08-24 | — | — | US | claimed |
| US-20230255920-A1 | METHOD FOR TREATING METASTATIC PROSTATE CANCER | THE WILLIAM M YARBROUGH FOUNDATION | 2023-08-17 | — | — | US | claimed |
| US-6531444-B1 | Fragrant burst upon ironing; hydrophobic candelilla wax/silicon copolymer; cationic charge boosters and fabric softeners | SALVONA, LLC | 2003-03-11 | — | — | US | claimed |
| US-20020122781-A1 | Cosmetic compositions containing heteropolymers and oil-soluble cationic surfactants and methods of using same | PINZON CARLOS O (US) | 2002-09-05 | — | — | US | claimed |
| WO-2002047620-A2 | COMPOSITIONS CONTAINING HETEROPOLYMERS AND METHODS OF USING SAME | L'OREAL SA (FR) | 2002-06-20 | — | — | WO | claimed |
| WO-2002047658-A2 | COSMETIC COMPOSITIONS CONTAINING HETEROPOLYMERS AND OIL-SOLUBLE CATIONIC SURFACTANTS AND METHODS OF USING SAME | L'OREAL SA (FR) | 2002-06-20 | — | — | WO | claimed |
| WO-2002038713-A1 | A CONTROLLED DELIVERY SYSTEM FOR FABRIC CARE PRODUCTS | SALVONA, L.L.C. (US) | 2002-05-16 | — | — | WO | claimed |
| US-6147038-A | MIXTURE CONTAINING DIALKYLQUATERNARY AMINE SALT; HAIR CONDITIONER | DOW CORNING CORPORATION (US) | 2000-11-14 | — | — | US | claimed |
| EP-0705864-B1 | Method of emulsion polymerization | DOW CORNING (US) | 2000-03-01 | — | — | EP | claimed |
| EP-0955288-A2 | Dialkylquat and trialkylquat benzoate and salicylate salts | WITCO CORPORATION (US) | 1999-11-10 | — | — | EP | claimed |
| EP-0705864-A1 | Method of emulsion polymerization | DOW CORNING CORPORATION (US) | 1996-04-10 | — | — | EP | claimed |
| US-5504149-A | MIXING WATER, CYCLIC SILOXANE, NONIONIC SURFACTANT, CATIONIC SURFACTANT, ADDING SILANOLATE POLYMERIZATION INITIATOR, HEATING, AGITATING, POLYMERIZING TO SILICONE EMULSION | DOW CORNING CORPORATION (US) | 1996-04-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020122781-A1 | Cosmetic compositions containing heteropolymers and oil-soluble cationic surfactants and methods of using same | SYMPK, CUTA, LSS | LPAR3 289/4885LPAR1 368/4885LPAR2 278/4885 |
| US-20260055056-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | ALK, C9, MSR1 | LPAR3 769/4885LPAR1 1691/4885LPAR2 1604/4885 |
| US-12178795-B2 | Method for treating metastatic prostate cancer | BPHL, KLK3, ACP3 | LPAR3 309/4885LPAR1 895/4885LPAR2 1204/4885 |
| US-12239626-B2 | Method for treating infectious diseases with isothiocyanate functional compounds | CFTR, TST, ICMT | LPAR3 4406/4885LPAR1 4336/4885LPAR2 4541/4885 |
| US-12310939-B2 | Method for treating rheumatoid arthritis | MIF, TNF, MMP12 | LPAR3 2643/4885LPAR1 2561/4885LPAR2 2673/4885 |
| US-20250161258-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | TST, TMSB10, NHERF1 | LPAR3 2765/4885LPAR1 3171/4885LPAR2 3703/4885 |
| US-20230338324-A1 | METHOD FOR TREATING RHEUMATOID ARTHRITIS | MIF, TNF, MMP12 | LPAR3 2071/4885LPAR1 1951/4885LPAR2 2157/4885 |
| US-20230263763-A1 | METHOD FOR TREATING INFECTIOUS DISEASES WITH ISOTHIOCYANATE FUNCTIONAL COMPOUNDS | CFTR, TST, ICMT | LPAR3 4406/4885LPAR1 4336/4885LPAR2 4541/4885 |
| US-20230255920-A1 | METHOD FOR TREATING METASTATIC PROSTATE CANCER | BPHL, KLK3, ACP3 | LPAR3 309/4885LPAR1 895/4885LPAR2 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.